REEMON BISHARA: Open Payments
NPI 1750308623 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$950 in 23 payments from 9 companies in 2025. Trend: 2023 $572 · 2024 $832 · 2025 $950
Food & beverage: $950
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $178 |
| Axsome Therapeutics, Inc. | 3 | $178 |
| Janssen Pharmaceuticals, Inc | 3 | $170 |
| Neurocrine BioSciences, Inc. | 1 | $119 |
| E.R. Squibb & Sons, L.L.C. | 3 | $107 |
| Teva Pharmaceuticals USA, Inc. | 4 | $88 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $42 |
| Alkermes, Inc. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
Products named: Auvelity, INVEGA SUSTENNA, ABILIFY MAINTENA, INGREZZA, COBENFY, UZEDY, ABILIFY ASIMTUFII, ARISTADA.
Industry payments across NY — which companies pay providers there.
